VERU Quote, Financials, Valuation and Earnings

Altimmune has a net margin of -128.15% compared to Veru's net margin of -463600%. Veru's return on equity of -101.38% beat Altimmune's return on equity of -61.21%.

Veru has a consensus price target of $3.25, signalling upside risk potential of 545.48%. On the other hand Altimmune has an analysts' consensus of $22.38 which suggests that it could grow by 300.27%. Given that Veru has higher upside potential than Altimmune, analysts believe Veru is more attractive than Altimmune.

Veru has a beta of -0.741, which suggesting that the stock is 174.082% less volatile than S&P 500. In comparison Altimmune has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.05%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Altimmune quarterly revenues of $5K. Veru's net income of -$8.9M is higher than Altimmune's net income of -$23.2M. Notably, Veru's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 4.20x versus 19,847.49x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

Arrowhead Pharmaceuticals has a net margin of -128.15% compared to Veru's net margin of -6923.4%. Veru's return on equity of -101.38% beat Arrowhead Pharmaceuticals's return on equity of -254.82%.

Veru has a consensus price target of $3.25, signalling upside risk potential of 545.48%. On the other hand Arrowhead Pharmaceuticals has an analysts' consensus of $45.64 which suggests that it could grow by 250.29%. Given that Veru has higher upside potential than Arrowhead Pharmaceuticals, analysts believe Veru is more attractive than Arrowhead Pharmaceuticals.

Veru has a beta of -0.741, which suggesting that the stock is 174.082% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.532%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Arrowhead Pharmaceuticals quarterly revenues of $2.5M. Veru's net income of -$8.9M is higher than Arrowhead Pharmaceuticals's net income of -$173.1M. Notably, Veru's price-to-earnings ratio is -- while Arrowhead Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 4.20x versus 12.45x for Arrowhead Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Structure Therapeutics has a net margin of -128.15% compared to Veru's net margin of --. Veru's return on equity of -101.38% beat Structure Therapeutics's return on equity of --.

Veru has a consensus price target of $3.25, signalling upside risk potential of 545.48%. On the other hand Structure Therapeutics has an analysts' consensus of $78.86 which suggests that it could grow by 208.4%. Given that Veru has higher upside potential than Structure Therapeutics, analysts believe Veru is more attractive than Structure Therapeutics.

Veru has a beta of -0.741, which suggesting that the stock is 174.082% less volatile than S&P 500. In comparison Structure Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Structure Therapeutics pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Structure Therapeutics quarterly revenues of --. Veru's net income of -$8.9M is higher than Structure Therapeutics's net income of -$36.5M. Notably, Veru's price-to-earnings ratio is -- while Structure Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 4.20x versus -- for Structure Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -128.15% compared to Veru's net margin of --. Veru's return on equity of -101.38% beat Viking Therapeutics's return on equity of --.

Veru has a consensus price target of $3.25, signalling upside risk potential of 545.48%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 227.63%. Given that Veru has higher upside potential than Viking Therapeutics, analysts believe Veru is more attractive than Viking Therapeutics.

Veru has a beta of -0.741, which suggesting that the stock is 174.082% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Veru has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veru pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Veru quarterly revenues are $6.7M, which are larger than Viking Therapeutics quarterly revenues of --. Veru's net income of -$8.9M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Veru's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veru is 4.20x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.